Viewing Study NCT02814669


Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-01-02 @ 9:19 AM
Study NCT ID: NCT02814669
Status: COMPLETED
Last Update Posted: 2019-09-24
First Post: 2016-06-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module